BAALC and acute myeloid leukemia: Subgroup analyses for patients harboring de novo disease (n=52, Supplementary Figure 2), patients transplanted in CR (n=68, Supplementary Figure 3), CD34-positive AML (n=31, Supplementary Figure 4), patients surviving longer than 100 days after HSCT (n=71, Supplementary Figure 5), as well as patients with diagnostic BAALC/ABL1 copy number information available (n=51, Supplementary Figure 6) are shown in the Supplementary Materials.